NCT02970682View on ClinicalTrials.gov

SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

March 31, 2019

Conditions
Breast Neoplasm
Interventions
DRUG

SFX-01

Stabilised Sulforaphane

DRUG

Fulvestrant

Fulvestrant

DRUG

Tamoxifen

Tamoxifen

DRUG

Aromatase Inhibitors

Trial Locations (10)

100

Hospital Universitario Ramon Y Cajal, Madrid

1200

Saint-Luc hospital, Brussels, Woluwe-Saint-Lambert

6000

Grand Hopital de Charleroi, Service D'Oncologie-Hematologie, Charleroi

44805

ICO René Gauducheau, St Herblain, Nantes

Unknown

Granollers Hospital, Granollers,, Barcelona

M20 4BX

The Christie NHS Foundation Trust, Manchester

B15 2TH

University Hospitals Birmingham NHS Foundation, Birmingham

BH7 7DW

Royal Bournemouth & Christchurch Hospitals NHS, Bournemouth

S10 2SJ

Academic unit of Clinical Oncology, Sheffield

WN1 2WN

Royal Albert & Edward Infirmary, Wigan

Sponsors

Lead Sponsor

Evgen Pharma
All Listed Sponsors
collaborator

Premier Research Group plc

UNKNOWN

lead

Evgen Pharma

INDUSTRY